Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Takeda Pharmaceutical : Supports Launch of Five-Year, $1M Initiative Spearheaded by the Massachusetts Life Sciences Center to Back Women-Driven Early Stage Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 08:16pm CEST

Competitive Program to Award Two Recipients Annually with Funding and Mentorship –

Takeda Pharmaceutical Company Limited (TSE:4502) today announced its support of the launch of the MassNextGen initiative, a five-year, $1M program anchored by Takeda and matched by the Massachusetts Life Sciences Center (MLSC), to support women-led or controlled early-stage biotech companies. This highly competitive program aims to provide a year-long customized package of support that includes funding and executive coaching. The announcement was made today at Takeda Boston, which included Massachusetts Governor Charles Baker.

“Despite being essential members of the life sciences industry, women continue to be underrepresented, including at the executive level in which there remains a large gender gap,” said Christophe Bianchi M.D., President, Takeda Global Oncology Business Unit, Takeda Boston Site Head. “As an organization committed to diversity and inclusion, our contributions to the MassNextGen program and collaboration with the Massachusetts Life Sciences Center will further elevate the innovations that are being created by women-led companies, which have strong potential to make a difference in the future of our industry and the lives of patients.”

“The strength of startup life sciences companies is critical to Massachusetts innovation economy and we are committed to building diversity and empowering more women entrepreneurs in this growing field,” said Governor Charlie Baker. “This initiative will help more women-led companies to thrive, leveraging additional sources of capital and support to create new jobs and bring cutting edge innovation to the marketplace.”

“We are thrilled to begin this initiative with a strong partner in Takeda, and we look forward to collaborating with more companies, organizations and leaders to tackle this important issue,” said Lt. Governor Karyn Polito. “Through STEM-training initiatives and private sector partnerships like these, our administration is committed to increasing the representation of women in the life sciences.”

Each year, beginning in January 2018, a panel of judges comprised of representatives from MLSC, Takeda and the Executive Coaching network will select two women-owned/controlled early-stage companies to receive a year-long customized package of support through the MassNextGen program. The criteria used to determine winners will include level of involvement of women in the conception, strategy and execution of the company, the proposed use of the funds and the business plan feasibility. Each customized package will include both funding and access to a network of executive coaches that will help support, advise, and mentor the recipients.

Proposals for the first year of the program are due in February. For more information about the MassNextGen program, please visit: www.masslifesciences.com/programs/massnextgen.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.

© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
07/20TAKEDA PHARMACEUTICAL : Investigators from Takeda Pharmaceutical Company Have Re..
07/20TAKEDA PHARMACEUTICAL : and Ovid partner to start TAK-935/OV935 clinical trials
07/20TAKEDA PHARMACEUTICAL : Phase 3 Trial of NINLARO® ixazomib as Maintenance Therap..
07/20TAKEDA PHARMACEUTICAL : New Findings from Takeda Pharmaceutical Company in the A..
07/20TAKEDA PHARMACEUTICAL : Patent Issued for Method for Producing Dopaminergic Neur..
07/19TAKEDA PHARMACEUTICAL : Investigational Subcutaneous Vedolizumab Meets Primary E..
07/19TAKEDA PHARMACEUTICAL : and Ovid Therapeutics Expand Clinical Program for TAK-93..
07/19TAKEDA PHARMACEUTICAL : Submits an Application for a New Indication of Entyvio (..
07/19TAKEDA PHARMACEUTICAL : New Phase 3 Data Show Investigational Subcutaneous Formu..
07/18TAKEDA PHARMACEUTICAL : and Ovid Therapeutics Expand Clinical Program for TAK-93..
More news
News from SeekingAlpha
07/203 THINGS IN BIOTECH, JULY 20 : The Specter Haunts This Small Biotech 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19Subcutaneous formulation of Takeda's vedolizumab shows treatment effect in la.. 
07/18FDA committed to easing approval path for biosimilars 
07/18Takeda and Ovid Therapeutics expand clinical program for TAK-935/OV935 
Financials (JPY)
Sales 2019 1 762 B
EBIT 2019 -
Net income 2019 160 B
Debt 2019 680 B
Yield 2019 3,81%
P/E ratio 2019 22,99
P/E ratio 2020 20,31
EV / Sales 2019 2,52x
EV / Sales 2020 2,36x
Capitalization 3 762 B
Duration : Period :
Takeda Pharmaceutical Co L Technical Analysis Chart | 4502 | JP3463000004 | 4-Traders
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 6 339  JPY
Spread / Average Target 34%
EPS Revisions
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171